Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE

INTRODUCTION: The phase IIIb open-label ODYSSEY APPRISE study prospectively assessed the safety and efficacy of alirocumab (a proprotein convertase subtilisin/kexin type 9 [PCSK9] inhibitor) in a real-life setting in high cardiovascular risk patients with heterozygous familial hypercholesterolemia o...

Descripción completa

Detalles Bibliográficos
Autores principales: Banach, Maciej, López-Sendon, José Luis, Averna, Maurizio, Cariou, Bertrand, Loy, Megan, Manvelian, Garen, Batsu, Isabela, Poulouin, Yann, Gaudet, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924821/
https://www.ncbi.nlm.nih.gov/pubmed/35316922
http://dx.doi.org/10.5114/aoms/143476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924821/
https://www.ncbi.nlm.nih.gov/pubmed/35316922
http://dx.doi.org/10.5114/aoms/143476

Ejemplares similares